95 active
/
218 total (since 2015)
61
Phase 1 Active
128 total
52
Phase 2 Active
117 total
3
Phase 3 Active
14 total
0
Phase 4 Active
3 total
Top Sponsors (Industry)
Sorted by active Active Done Failed
Novartis 3 0 0
NGM Biopharmaceuticals, Inc 3 0 0
Seagen, a wholly owned subsidiary of Pfizer 2 0 0
TCR2 Therapeutics 2 0 0
Bristol-Myers Squibb 1 2 0
Merck 1 1 0
AstraZeneca 1 0 0
Nuvectis Pharma, Inc. 1 0 0
Genmab 1 0 0
A2 Biotherapeutics Inc. 1 0 0
InSilico Medicine Hong Kong Limited 1 0 0
Verismo Therapeutics 1 0 0
SpringWorks Therapeutics, Inc. 1 0 0
IDEAYA Biosciences 1 0 0
Perspective Therapeutics 1 0 0
NCT06097728 RECRUITING
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
AstraZeneca n=825
NCT03710876 ACTIVE NOT RECRUITING
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Ferring Ventures Limited n=53
NCT04996017 RECRUITING
Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)
Gruppo Oncologico Italiano di Ricerca Clinica n=162
NCT04334759 COMPLETED
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
PrECOG, LLC. n=214
NCT03762018 COMPLETED
BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma
ETOP IBCSG Partners Foundation n=401
NCT03063450 COMPLETED
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
University of Southampton n=332
NCT04158141 TERMINATED
Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma
NRG Oncology n=16
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT02784171 COMPLETED
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group n=520
NCT02899299 COMPLETED
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Bristol-Myers Squibb n=605
NCT02709512 COMPLETED
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
Polaris Group n=249
NCT02991482 COMPLETED
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma
ETOP IBCSG Partners Foundation n=144
NCT02511600 WITHDRAWN
Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication
M.D. Anderson Cancer Center
NCT05647265 RECRUITING
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
Alliance for Clinical Trials in Oncology
NCT05703854 RECRUITING
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
M.D. Anderson Cancer Center
NCT06654050 NOT YET RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
National Cancer Institute (NCI)
NCT05579366 RECRUITING
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
NCT06051695 RECRUITING
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
A2 Biotherapeutics Inc.
NCT07234058 NOT YET RECRUITING
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
Intergroupe Francophone de Cancerologie Thoracique
NCT06710756 RECRUITING
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Perspective Therapeutics
NCT06155279 ACTIVE NOT RECRUITING
Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study)
Istituto Oncologico Veneto IRCCS
NCT07282873 NOT YET RECRUITING
Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors
TYK Medicines, Inc
NCT03556228 RECRUITING
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
NCT05001880 RECRUITING
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
National Cancer Institute (NCI)
NCT05730816 RECRUITING
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
Brigham and Women's Hospital
NCT06503146 RECRUITING
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT03007030 RECRUITING
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
NCT02535312 ACTIVE NOT RECRUITING
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
National Cancer Institute (NCI)
NCT04665206 RECRUITING
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Vivace Therapeutics, Inc
NCT03126630 ACTIVE NOT RECRUITING
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
National Cancer Institute (NCI)
NCT02414269 ACTIVE NOT RECRUITING
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Memorial Sloan Kettering Cancer Center
NCT06790706 RECRUITING
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Hospices Civils de Lyon
NCT05932199 RECRUITING
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Baylor College of Medicine
NCT06840834 RECRUITING
Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy
Intergroupe Francophone de Cancerologie Thoracique
NCT02628067 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
Merck Sharp & Dohme LLC
NCT06362369 RECRUITING
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
NCT03074513 ACTIVE NOT RECRUITING
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
NCT05451849 ACTIVE NOT RECRUITING
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT03907852 ACTIVE NOT RECRUITING
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT07131345 NOT YET RECRUITING
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
National Cancer Center, China
NCT07121374 RECRUITING
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
University Hospital, Antwerp
NCT06057935 RECRUITING
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT06477419 RECRUITING
A Study of Sacituzumab Govitecan in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT03935893 RECRUITING
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT06790082 RECRUITING
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma
Aalborg University Hospital
NCT03918252 ACTIVE NOT RECRUITING
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02399371 ACTIVE NOT RECRUITING
Pembrolizumab in Treating Patients With Malignant Mesothelioma
University of Chicago
NCT05188859 RECRUITING
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT06638931 ACTIVE NOT RECRUITING
Agnostic Therapy in Rare Solid Tumors
Instituto do Cancer do Estado de São Paulo
NCT06318286 RECRUITING
Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma
Hyogo Medical University
NCT04104776 RECRUITING
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis Pharmaceuticals
NCT04802876 ACTIVE NOT RECRUITING
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
SOLTI Breast Cancer Research Group
NCT06875076 RECRUITING
Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma
The First Hospital of Jilin University
NCT04287829 ACTIVE NOT RECRUITING
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
The Netherlands Cancer Institute
NCT04913337 ACTIVE NOT RECRUITING
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals, Inc
NCT06543069 RECRUITING
Sintilimab, Bevacizumab, Pemetrexed, and Cisplatin for Unresectable MPeM
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05765084 RECRUITING
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma
University Hospital, Antwerp
NCT06416930 NOT YET RECRUITING
Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NCT05425576 NOT YET RECRUITING
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Oncotelic Inc.
NCT04300244 ACTIVE NOT RECRUITING
Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
Åslaug Helland
NCT05930665 RECRUITING
Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma
Sun Yat-sen University
NCT05960773 SUSPENDED
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Cancer Institute (NCI)
NCT07411144 COMPLETED
Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma
National Cancer Institute, Egypt
NCT03875144 SUSPENDED
Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)
Institut du Cancer de Montpellier - Val d'Aurelle
NCT02662504 COMPLETED
Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma
University Hospital, Lille
NCT05136677 COMPLETED
A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants
Bristol-Myers Squibb
NCT05070247 TERMINATED
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
NCT03075527 TERMINATED
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
Dana-Farber Cancer Institute
NCT05005429 COMPLETED
Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma
Fundación GECP
NCT02611037 COMPLETED
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
H. Lee Moffitt Cancer Center and Research Institute
NCT05795595 COMPLETED
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics AG
NCT02875548 COMPLETED
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
Epizyme, Inc.
NCT05337735 SUSPENDED
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
NCT04914897 TERMINATED
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Sanofi
NCT02863055 TERMINATED
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
European Organisation for Research and Treatment of Cancer - EORTC
NCT05449366 COMPLETED
Intraperitoneal Paclitaxel for Patients With Primary Malignant Peritoneal Mesothelioma
Erasmus Medical Center
NCT05714553 TERMINATED
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
NCT05563272 TERMINATED
89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
Telix Pharmaceuticals (Innovations) Pty Ltd
NCT02611024 COMPLETED
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
NCT05455424 COMPLETED
Niraparib Efficacy in Patient With Unresectable Mesothelioma
University Hospital Southampton NHS Foundation Trust
NCT02649829 COMPLETED
Autologous Dendritic Cell Vaccination in Mesothelioma
University Hospital, Antwerp
NCT03560973 COMPLETED
A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
Gruppo Oncologico Italiano di Ricerca Clinica
NCT04177953 COMPLETED
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
NCT05500508 TERMINATED
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
NCT05660616 COMPLETED
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Ain Shams University
NCT04480372 COMPLETED
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Swiss Cancer Institute
NCT03319537 TERMINATED
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT03502746 TERMINATED
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma
Arkadiusz Z. Dudek, MD
NCT03393858 TERMINATED
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma
Capital Medical University
NCT05041062 COMPLETED
A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
University of Chicago
NCT03399552 COMPLETED
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT06090318 WITHDRAWN
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
NCT03207347 COMPLETED
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
NCT02899195 COMPLETED
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
PrECOG, LLC.
NCT05582031 WITHDRAWN
Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
Translational Research in Oncology
NCT03233724 TERMINATED
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Cancer Institute (NCI)
NCT04115111 COMPLETED
Diadem to Investigate the Activity and Safety of Durvalumab
Mario Negri Institute for Pharmacological Research
NCT02414945 COMPLETED
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
University Health Network, Toronto
NCT02293005 COMPLETED
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
M.D. Anderson Cancer Center
NCT02592551 COMPLETED
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
Baylor College of Medicine
NCT02385812 TERMINATED
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma
University of Calgary
NCT02347917 COMPLETED
A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
Sumitomo Pharma Co., Ltd.
NCT02859415 TERMINATED
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Cancer Institute (NCI)
NCT02568449 COMPLETED
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
Barbara Ann Karmanos Cancer Institute
NCT03644550 TERMINATED
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
National Cancer Institute (NCI)
NCT02408016 TERMINATED
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Fred Hutchinson Cancer Center
NCT03213301 COMPLETED
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
Swiss Cancer Institute
NCT03786419 WITHDRAWN
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Health Pharma Professional Research
NCT02860286 COMPLETED
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
Epizyme, Inc.
NCT03531840 COMPLETED
Olaparib in People With Malignant Mesothelioma
National Cancer Institute (NCI)
NCT02716272 COMPLETED
Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
Intergroupe Francophone de Cancerologie Thoracique
NCT03048474 COMPLETED
Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
The Netherlands Cancer Institute
NCT02610140 COMPLETED
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Bayer
NCT03177668 COMPLETED
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
Kissei Pharmaceutical Co., Ltd.
NCT02357147 TERMINATED
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
Morphotek
NCT03175172 TERMINATED
Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
Aduro Biotech, Inc.
NCT02397928 COMPLETED
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
NovoCure Ltd.
NCT01627795 SUSPENDED
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Oshadi Drug Administration
NCT02497508 COMPLETED
Nivolumab in Patients With Recurrent Malignant Mesothelioma
The Netherlands Cancer Institute
NCT02661100 WITHDRAWN
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
Case Comprehensive Cancer Center
NCT04491942 ACTIVE NOT RECRUITING
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
NCT05873686 RECRUITING
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
NCT07443020 NOT YET RECRUITING
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
NCT04847063 RECRUITING
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
National Cancer Institute (NCI)
NCT06885697 RECRUITING
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
NCT06566079 RECRUITING
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
InSilico Medicine Hong Kong Limited
NCT05568680 RECRUITING
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Verismo Therapeutics
NCT04897022 RECRUITING
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT07277413 RECRUITING
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
NCT07192900 RECRUITING
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
David Bartlett, MD
NCT06466187 ACTIVE NOT RECRUITING
A Study of SGN-MesoC2 in Advanced Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05544929 ACTIVE NOT RECRUITING
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Novartis Pharmaceuticals
NCT05571839 ACTIVE NOT RECRUITING
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer
NCT05245500 RECRUITING
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Bristol-Myers Squibb
NCT03760575 RECRUITING
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Abramson Cancer Center at Penn Medicine
NCT03983954 ACTIVE NOT RECRUITING
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NCT05238883 ACTIVE NOT RECRUITING
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
HiFiBiO Therapeutics
NCT02959463 ACTIVE NOT RECRUITING
Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
M.D. Anderson Cancer Center
NCT03228537 ACTIVE NOT RECRUITING
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
NCT04857372 ACTIVE NOT RECRUITING
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Novartis Pharmaceuticals
NCT04162015 ACTIVE NOT RECRUITING
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT05107674 RECRUITING
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
NCT06756035 RECRUITING
CT-95 in Advanced Cancers Associated With Mesothelin Expression
Context Therapeutics Inc.
NCT04577326 ACTIVE NOT RECRUITING
Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT03678350 ACTIVE NOT RECRUITING
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Roswell Park Cancer Institute
NCT05304208 RECRUITING
dENdritic Cell Therapy Combined With SURgEry in Mesothelioma
Erasmus Medical Center
NCT03212404 ACTIVE NOT RECRUITING
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
NCT06726564 RECRUITING
A Study of MT027 in Patients with Pleural Malignant Tumors
Suzhou Maximum Bio-tech Co., Ltd.
NCT06652529 NOT YET RECRUITING
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
Aromics Therapeutics
NCT05215574 ACTIVE NOT RECRUITING
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NCT03546426 ACTIVE NOT RECRUITING
Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NCT06452160 RECRUITING
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
BridGene Biosciences Inc.
NCT06256055 RECRUITING
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
NCT06196294 RECRUITING
GPC3/Mesothelin-CAR-γδT Cells Against Cancers
Second Affiliated Hospital of Guangzhou Medical University
NCT05311618 ACTIVE NOT RECRUITING
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals, Inc
NCT05698238 NOT YET RECRUITING
Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours
Mabpro, a.s.
NCT05627960 RECRUITING
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
A&G Pharmaceutical Inc.
NCT03420963 TERMINATED
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
NCT04166734 TERMINATED
Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
Royal Marsden NHS Foundation Trust
NCT04272034 TERMINATED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT02903914 COMPLETED
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
NCT06299163 TERMINATED
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
NCT04153565 COMPLETED
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
Merck Sharp & Dohme LLC
NCT04242199 COMPLETED
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Incyte Corporation
NCT03881488 COMPLETED
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
NCT04040231 COMPLETED
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT04301011 TERMINATED
Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
Turnstone Biologics, Corp.
NCT04537715 COMPLETED
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Epizyme, Inc.
NCT04234113 TERMINATED
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
SOTIO Biotech AG
NCT05228015 TERMINATED
Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors
Ikena Oncology
NCT06034860 TERMINATED
Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types
Molecular Templates, Inc.
NCT02707666 TERMINATED
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
University of Chicago
NCT05538572 COMPLETED
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Prelude Therapeutics
NCT04840615 TERMINATED
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Cancer Institute (NCI)
NCT05375825 WITHDRAWN
Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
National Cancer Institute (NCI)
NCT05071014 COMPLETED
A Study of Pembrolizumab and Cryoablation in People With Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT04034238 COMPLETED
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
National Cancer Institute (NCI)
NCT03507452 COMPLETED
First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin
Bayer
NCT04430842 COMPLETED
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
Quadriga Biosciences, Inc.
NCT03517488 COMPLETED
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Xencor, Inc.
NCT02555007 COMPLETED
Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM
Assistance Publique Hopitaux De Marseille
NCT02798536 COMPLETED
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
National Cancer Institute (NCI)
NCT03023319 COMPLETED
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Nagla Abdel Karim
NCT04173338 TERMINATED
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
Augusta University
NCT02838745 TERMINATED
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
Baylor College of Medicine
NCT04481672 COMPLETED
Intravenous Magnesium in Patients Receiving Cisplatin
Dana-Farber Cancer Institute
NCT03652077 COMPLETED
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
NCT03608618 TERMINATED
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
MaxCyte, Inc.
NCT03538028 COMPLETED
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Biosciences International Sàrl
NCT03920839 WITHDRAWN
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
Incyte Corporation
NCT03436732 TERMINATED
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
National Cancer Institute (NCI)
NCT02661659 WITHDRAWN
A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
University of Chicago
NCT02567396 WITHDRAWN
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
NCT02372227 TERMINATED
A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
Verastem, Inc.
NCT02639767 WITHDRAWN
Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center
NCT03656549 COMPLETED
Dose Individualization of Pemetrexed - IMPROVE-I
Radboud University Medical Center
NCT03655821 TERMINATED
Dose Individualization of Pemetrexed - IMPROVE-II
Radboud University Medical Center
NCT03655834 COMPLETED
Dose Individualization of Pemetrexed - IMPROVE-III
Radboud University Medical Center
Data: ClinicalTrials.gov